← Back to Search

Monoclonal Antibodies

Hu8F4 for Blood Cancers

Phase 1
Waitlist Available
Led By Tapan M Kadia
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 years
Awards & highlights

Study Summary

This trial looks at the side effects and best dose of the drug Hu8F4 for treating patients with blood cancers. The drug may help stop cancer cells from growing and spreading.

Who is the study for?
This trial is for adults with advanced blood-related cancers like certain types of leukemia, myelodysplastic syndrome, or myelofibrosis. Participants must have specific genetic traits (HLA-A2), failed previous treatments, and be in good enough health to tolerate the study drug. Pregnant women are excluded and contraception is required during the trial.Check my eligibility
What is being tested?
The trial tests Hu8F4, a monoclonal antibody that may block cancer growth. It's in phase I to determine safe dosage levels and side effects. Patients will undergo lab biomarker analysis and pharmacological studies to see how well Hu8F4 works against their cancer.See study design
What are the potential side effects?
Potential side effects of Hu8F4 could include typical reactions seen with other monoclonal antibodies such as allergic reactions at the infusion site, fever, chills, nausea, fatigue, headache or more serious immune system related problems.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Biologically-effective dose
Minimum safety data
Secondary outcome measures
Disease
Duration of complete remission
Event-free survival
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (Hu8F4)Experimental Treatment3 Interventions
Patients receive anti-PR1/HLA-A2 monoclonal antibody Hu8F4 IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,987 Previous Clinical Trials
1,798,163 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,717 Previous Clinical Trials
40,953,291 Total Patients Enrolled
1 Trials studying Blood Cancers
70 Patients Enrolled for Blood Cancers
Tapan M KadiaPrincipal InvestigatorM.D. Anderson Cancer Center
13 Previous Clinical Trials
1,191 Total Patients Enrolled

Media Library

Blood Cancers Research Study Groups: Treatment (Hu8F4)
Hu8F4 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02530034 — Phase 1
~11 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top